Brian Joseph Cahill - 27 Feb 2024 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Brian Cahill
Issuer symbol
EGRX
Transactions as of
27 Feb 2024
Net transactions value
-$10,233
Form type
4
Filing time
29 Feb 2024, 20:23:05 UTC
Previous filing
06 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EGRX Common Stock Award $0 +3,800 +8.3% $0.000000 49,547 27 Feb 2024 Direct F1
transaction EGRX Common Stock Tax liability $10,233 -1,589 -3.2% $6.44 47,958 27 Feb 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents common stock issued upon satisfaction of certain performance criteria contained in performance stock units ("PSUs") granted in 2021.
F2 The disposition reported on this Form 4 represents shares withheld by the Issuer to cover the tax liability upon the vesting of the PSUs and does not represent a discretionary transaction by the Reporting Person.